FOXO4-DRI is a synthetic version of FOXO4, containing D amino acids instead of L amino acids. This modification is intended to allow the peptide to retain the functionality of the original protein but with a longer shelf life and lower clearance. Its most prominent function has been suggested to regulate apoptosis in senescent cells.^[1] It has been suggested in scientific studies that senescent cells might exhibit resistance to apoptosis, aka programmed cell death. This resistance has been associated with increased binding of FOXO4 with another protein, p53, which should trigger apoptosis but become inactivated.

FOXO4-DRI appears to work by inhibiting FOXO4-p53 binding; thereby, p53 may target pro-apoptotic genes and promote their expression. These proteins, in turn, may induce apoptosis of old cells, thereby reducing the old cell burden in tissues. The accumulation of senescent cells, often referred to as the “old cell burden,” is a concern because these cells can secrete a variety of harmful substances as part of the senescence-associated secretory phenotype (SASP). SASP is characterized by the release of inflammatory and tissue-degrading molecules that can impair tissue function and structure, potentially leading to age-related deterioration. By possibly disrupting the harmful cycle of senescent cell accumulation through the action of FOXO4-DRI, there might be an improvement in tissue function. This restoration of tissue function could also be accompanied by a reduction in the biomarkers associated with cellular aging, suggesting a return toward a more balanced state of cell function.

This may also lead to increases in cellular differentiation and tissue repair. FOXO4 protein is a prominent member of the group of transcription factors classified as exhibiting potential to regulate growth and differentiation. It appears to be endogenously abundant in tissues such as the placenta, ovaries, fat cells, testes, and adrenal glands. Post-translational modifications, especially those in the DNA binding domain of FOXO4 protein, appear to modify its functionality as a transcription factor and regulation of pathways such as apoptosis, cellular senescence, insulin signaling, and senescence.

FOXO4-D-Retro-Inverso is a synthetic and partially altered form of the original FOXO4 protein. The modification was developed to help enhance the half-life of the protein and allow it to obstruct the normal FOXO4 function. FOXO4-DRI has been suggested to prevent normal FOXO4 binding to p53, eliminate senescent cells, enhance organ function, and reduce cell death progression. FOXO4-DRI also appears to influence insulin signaling, cell cycle regulation, and oxidative stress signaling pathways. The peptide appears to be permeable into cells, and researchers have suggested selectively inducing senescent cell apoptosis based on results found in studies.